Integrated proteogenomic and metabolomic profiling of acute myeloid leukemias to identify molecular subtypes and associated therapy targets

1

Acute myeloid leukemia (AML) is a heterogeneous malignancy with a low 5-year survival rate of 30% and high relapse rates.
2

Recent FDA-approved targeted therapies are used for AML patients with specific genetic mutations like IDH1 and FLT3 ITD.
3

A multiomic atlas of 173 treatment-naive AML patients identified eight distinct subtypes linking genetic drivers to molecular traits.
4

The study utilized comprehensive sequencing and mass spectrometry to analyze genomics, proteomics, and metabolomics in AML.
5

NPM1 mutations significantly impact protein levels and post-translational modifications, affecting AML biology and treatment responses.

Nature Cancer

by Shih-Chun A. Chu, Yi Hsiao, Chenwei Wang, Jennifer E. Kyle, Raghav Jain, Yamei Deng, Marina A. Gritsenko, Leanne E. Henry, Jonathan T. Lei, Yongchao Dou, Bahar Tercan, Zhiao Shi, Mahnoor N. Gondal, Chia-Feng Tsai, John M. Elizarraras, Rosalie K. Chu, Fengchao Yu, Sunil K. Joshi, Xiaojun Jing, Daniel A. Polasky, Karl K. Weitz, Ginny Xiaohe Li, Vanessa L. Paurus, Chaevien S. Clendinen, Athena A. Schepmoes, Priscila M. Lalli, Josie G. Eder, Javier E. Flores, Kelly G. Stratton, James C. Pino, Camilo Posso, Vladislav A. Petyuk, Tyler J. Sagendorf, Yuanwei Xu, Omar M. Ibrahim, Ronald J. Moore, Rui Zhao, Jin Chen, Matthew E. Monroe, Mathangi Thiagarajan, Galen Hostetter, Chelsea Newton, Eunkyung An, Ana I. Robles, Xu Zhang, Nathan J. Edwards, Yin Lu, Hui Zhang, Haitham Abdelhakim, Paul D. Piehowski, Mehdi Mesri, Richard D. Smith, Chandan Kumar-Sinha, Cristina E. Tognon, Jennifer Dunlap, Elie Traer, Li Ding, Jeffrey W. Tyner, Arul M. Chinnaiyan, Gilbert S. Omenn, Karin D. Rodland, Saravana M. Dhanasekaran, Sara J. C. Gosline, Alexey I. Nesvizhiskii, Bing Zhang, Tao Liu, Marcin P. Cieslik
June 12, 2026

1